isirv

Forthcoming Influenza and Antiviral Conferences

Previous Influenza and Antiviral Conferences

Antiviral Group virtual Conference on ‘Therapeutics for COVID-19’

Over 300 attended this three day Antiviral Group virtual Conference on ‘Therapeutics for COVID-19’ 6-8 October 2020, introduced by Sir Jeremy Farrar, Director of the Wellcome Trust, London, who set the scene for a comprehensive programme of talks and discussions of recent research on this urgent topic at a particularly crucial time in the pandemic.

Registered participants can access recordings of the conference here.

The programme document is available here.

The Conference Report is available here.

Slides from oral presentations

• COVID-19 CLINICAL SPECTRUM, COMPLICATIONS, AND COINFECTIONS
• VIRAL REPLICATION KINETICS AND ANTIBODY RESPONSES
• IMMUNOPATHOGENESIS OF COVID-19
• PATHOGENESIS AND MANAGEMENT OF ARDS
• SOFOSBUVIR AND DACLATASVIR COMPARED TO STANDARD OF CARE IN THE TREATMENT OF PATIENTS WITH CORONAVIRUS INFECTION (COVID-19): A RANDOMISED CONTROLLED TRIAL
• INHIBITION OF SIRTUINS IS BROADLY EFFECTIVE AGAINST CORONAVIRUSES
• REPURPOSING OF CLINICALLY-APPROVED DRUGS FOR THE TREATMENT OF COVID-19
• FLUVOXAMINE FOR PREVENTION OF CLINICAL DETERIORATION IN EARLY COVID-19: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED TRIAL
• PRE-CLINICAL MODELS FOR DOWNSELECTING CANDIDATES
• CONVALESCENT PLASMA AND POLYCLONAL ANTIBODIES
• MONOCLONAL ANTIBODIES
• COMPLETE MAPPING OF MUTATIONS TO THE SARS-COV-2 SPIKE RECEPTOR-BINDING DOMAIN THAT ESCAPE ANTIBODY RECOGNITION
• BLOCKAGE OF CATHEPSIN L ACTIVITY BY SLV213, A NOVEL CYSTEINE PROTEASE INHIBITOR, PREVENTS SARS-COV-2 VIRAL ENTRY
• EFFECT OF JAK INHIBITOR TREATMENT ON CLINICAL OUTCOME, LUNG PATHOLOGY, AND VIRAL LOAD IN A MOUSE MODEL OF PATHOGENIC SARS-COV-2 INFECTION
• TREATMENT OF SEVERE COVID-19 WITH LOW-DOSE SELINEXOR: DEMONSTRATION OF ANTI-VIRAL AND ANTI-INFLAMMATORY ACTIVITIES IN A RANDOMIZED, INTERNATIONAL, MULTICENTER, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL
• MARGINAL EFFECT OF GC-376 AS A SARS-COV-2 ANTIVIRAL IN THE K18 hACE2 TRANSGENIC MOUSE MODEL
• A PHASE 2 STUDY OF LERONLIMAB FOR MILD TO MODERATE CORONAVIRUS DISEASE 2019 (COVID-19)
• SOLIDARITY TRIAL & LESSONS LEARNED
• REMDESIVIR
• EIDD-2801
• FAVIPIRIVIR
• JAK INHIBITORS
• TOCILIZUMAB IN COVID 19 - UPDATE
• OPERATION WARP SPEED THERAPEUTICS DEVELOPMENT
• DISCUSSION ON CLINICAL TRIAL ENDPOINTS

E-posters (click here for the list)

• Geographic correlation between the number of COVID-19 cases and the number of overseas travelers in Japan, January-February 2020
• Risk factors of viral RNAaemia and its association with clinical prognosis among patients with severe COVID-19
• Study on the Diagnostic Value of Blood Inflammatory Indicators in COVID-19
• A Rapid Review of the Asymptomatic Proportion of PCR-Confirmed SARS-CoV-2 Infections in Community Settings
• The SymptomSurvey: Patient and Caretaker Perspectives on COVID-19 Symptom Severity and the Expected Impact of Antivirals and Vaccines
• Understanding patients’ acceptability of self-collection of various clinical specimens to inform clinical diagnosis of COVID-19
• Quantitative proteomics characterization of respiratory viruses-exposed human primary T cells reveals host-pathogen interactions and therapy targets
• Transcriptional profiling of immune and inflammatory responses in the context of SARS-CoV-2 fungal superinfection in a human airway epithelial model
• Establishment of a novel real time PCR method to detect live SARS-CoV-2 in clinical samples
• The role of serological diagnosis in the study of the COVID-19 pathogenesis
• Characterization of spike activation and temperature dependence of SARS-CoV-2 and other human coronaviruses
• ICAM3 is a likely receptor for SARS CoV2 Entry
• Searching for antiviral strategies against a broad range of beta-CoV: Spike and Polymerase proteins as promising anti-CoV targets.
• Antiviral potential of distinct heparins against SARS-CoV-2 in vitro
• Guanosine as RNA Replication Blocker for Therapeutic Treatment of COVID 19
• AT-527, the oral prodrug of a guanosine nucleotide analog, is a potent in vitro inhibitor of SARS-CoV-2
• Plasma and tissue disposition of AT-527 and its active triphosphate metabolite in monkeys: implications for dose selection for patients with COVID-19
• Pre-planned meta-analysis of randomised trials of sofosbuvir-daclatasvir, to evaluate clinical benefits and survival
• Interpreting in-vitro data for sofosbuvir against SARS-CoV-2: cell lineage is key
• The in vitro antiviral activity of the anti-hepatitis C virus drugs daclatasvir and sofosbuvir against SARS-CoV-2.
• Role of 1’-Ribose Cyano Substitution for Remdesivir to Effectively Inhibit Nucleotide Addition and Proofreading in SARS-CoV-2 Viral RNA Replication
• Betulonic Acid Derivatives Interfering with Coronavirus Replication via the Nsp15 Endoribonuclease
• A Broad Inhibitor of Coronavirus Replication Acting via the Nsp15 Endoribonuclease
• Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry
• Broad-spectrum antiviral activity of naproxen: from Influenza A to SARS-CoV2 Coronavirus
• Long-Acting Intramuscular Injection of Niclosamide as a Broad Host-Directed Therapeutic Against SARS-CoV-2 and Other Viral Infections
• Acute, Suprapharmacologic Dexamethasone Mobilizes Natural Killer T and Cytotoxic T cells for COVID-19 ARDS
• Low-to-moderate dose corticosteroids Treatment in Hospitalized Adults With COVID-19

Congratulations to the awardees of Best Oral Presentation and Best Poster Presentation.

See you at our next conference!